EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer

Florien J G van Amstel, Cornelis M de Mooij iD, Janine M Simons, Cristina Mitea, Paul J van Diest, Patty J Nelemans, Carmen C van der Pol, Ernest J T Luiten, Linetta B Koppert, Marjolein L Smidt, Thiemo J A van Nijnatten iD, REFINE Study Group

British Journal of Surgery · 2024

DOI: 10.1093/bjs/znae203 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Florien J G van Amstel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Axilla, Breast Neoplasms, Fluorodeoxyglucose F18, Neoadjuvant Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University Fund Limburg, Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT combined with pathological axillary treatment response has been proposed to guide de-escalation of axillary treatment for clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy. The aim of this study was to assess whether axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and breast cancer molecular subtype are predictors of axillary pCR.

Methods

This study included clinically node-positive patients treated with neoadjuvant systemic therapy in the prospective Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy (‘RISAS’) trial (NCT02800317) with baseline [18F]fluorodeoxyglucose PET/CT imaging available. The predictive value of axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and breast cancer molecular subtype to estimate axillary pCR was evaluated using logistic regression analysis. Discriminative ability is expressed using ORs with 95% confidence intervals.

Results

Overall, 185 patients were included, with an axillary pCR rate of 29.7%. The axillary pCR rate for patients with limited versus advanced baseline axillary disease according to [18F]fluorodeoxyglucose PET/CT was 31.9% versus 26.1% respectively. Axillary disease extent was not a significant predictor of axillary pCR (OR 0.75 (95% c.i. 0.38 to 1.46) (P = 0.404)). There were significant differences in axillary pCR rates between breast cancer molecular subtypes. The lowest probability (7%) was found for hormone receptor+/human epidermal growth factor receptor 2− tumours. Using this category as a reference group, significantly increased ORs of 14.82 for hormone receptor+/human epidermal growth factor receptor 2+ tumours, 40 for hormone receptor−/human epidermal growth factor receptor 2+ tumours, and 6.91 for triple-negative tumours were found (P < 0.001).

Conclusion

Molecular subtype is a significant predictor of axillary pCR after neoadjuvant systemic therapy, whereas axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT is not.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AxillaBreast NeoplasmsFluorodeoxyglucose F18Neoadjuvant TherapyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedFemaleHumansMiddle AgedLymphatic MetastasisProspective StudiesSentinel Lymph Node BiopsyTreatment Outcome

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
  • Department of Radiotherapy, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Epidemiology, Maastricht University, Maastricht, The Netherlands.

ORCID-Profile: Cornelis M de Mooij, Thiemo J A van Nijnatten

Förderung

  • University Fund Limburg
  • Dutch Cancer Society

Zitieren

APA

van Amstel, F. J. G., de Mooij, C. M., Simons, J. M., Mitea, C., van Diest, P. J., Nelemans, P. J., van der Pol, C. C., Luiten, E. J. T., Koppert, L. B., Smidt, M. L., van Nijnatten, T. J. A., & REFINE Study Group (2024). Disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer. British Journal of Surgery. https://doi.org/10.1093/bjs/znae203

Vancouver

van Amstel FJG, de Mooij CM, Simons JM, Mitea C, van Diest PJ, Nelemans PJ, et al. Disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer. British Journal of Surgery. 2024. doi:10.1093/bjs/znae203

BibTeX
@article{vanAmstel2024,
  author = {van Amstel, Florien J G and de Mooij, Cornelis M and Simons, Janine M and Mitea, Cristina and van Diest, Paul J and Nelemans, Patty J and van der Pol, Carmen C and Luiten, Ernest J T and Koppert, Linetta B and Smidt, Marjolein L and van Nijnatten, Thiemo J A and REFINE Study Group, REFINE Study Group},
  title = {Disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer},
  journal = {British Journal of Surgery},
  year = {2024},
  doi = {10.1093/bjs/znae203}
}
Kostenlos starten →